Hilaire Yam Fung Cheung1,2,3, Cristina Coman1,4, Philipp Westhoff1, Mailin Manke5, Albert Sickmann1, Oliver Borst5, Meinrad Gawaz5, Steve P Watson2, Johan W M Heemskerk3, Robert Ahrends1,4. 1. Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V., 44227 Dortmund, Germany. 2. Institute of Cardiovascular Sciences, Institute of Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K. 3. Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 6229 ER Maastricht, The Netherlands. 4. Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, 1090 Wien, Austria. 5. Department of Cardiology and Cardiovascular Medicine, University of Tübingen, 72076 Tübingen, Germany.
Abstract
Phosphoinositides are minor components of cell membranes, but play crucial roles in numerous signal transduction pathways. To obtain quantitative measures of phosphoinositides, sensitive, accurate, and comprehensive methods are needed. Here, we present a quantitative targeted ion chromatography-mass spectrometry-based workflow that separates phosphoinositide isomers and increases the quantitative accuracy of measured phosphoinositides. Besides testing different analytical characteristics such as extraction and separation efficiency, the reproducibility of the developed workflow was also investigated. The workflow was verified in resting and stimulated human platelets, fat cells, and rat hippocampal brain tissue, where the LOD and LOQ for phosphoinositides were at 312.5 and 625 fmol, respectively. The robustness of the workflow is shown with different applications that confirms its suitability to analyze multiple less-abundant phosphoinositides.
Phosphoinositides are minor components of cell membranes, but play crucial roles in numerous signal transduction pathways. To obtain quantitative measures of phosphoinositides, sensitive, accurate, and comprehensive methods are needed. Here, we present a quantitative targeted ion chromatography-mass spectrometry-based workflow that separates phosphoinositide isomers and increases the quantitative accuracy of measured phosphoinositides. Besides testing different analytical characteristics such as extraction and separation efficiency, the reproducibility of the developed workflow was also investigated. The workflow was verified in resting and stimulated human platelets, fat cells, and rat hippocampal brain tissue, where the LOD and LOQ for phosphoinositides were at 312.5 and 625 fmol, respectively. The robustness of the workflow is shown with different applications that confirms its suitability to analyze multiple less-abundant phosphoinositides.
Entities:
Keywords:
ion chromatography; phosphoinositides; targeted lipidomics
Phosphoinositides are
one of the highly diverse glycerophospholipid
subcategories. Reversible phosphorylation of the myo-inositol headgroup
of phosphatidylinositol gives rise to seven distinct phosphoinositides
positional isomers in biological systems, namely, PtdIns3P, PtdIns4P,
PtdIns5P, PtdIns(3,4)P2, PtdIns(3,5)P2, PtdIns(4,5)P2, and PtdIns(3,4,5)P3. Phosphoinositides are versatile
signaling molecules crucial in signal transduction, especially PtdIns(4,5)P2 and PtdIns(3,4,5)P3, which play a central role
in the InsP3/DAG pathway[1] and
the PI3K/Akt pathway.[2,3] They also act as constitutive
signals that help define organelle identity and regulate protein localization
and membrane trafficking.[4] Hence, each
of the phosphoinositides has a specific spatial distribution pattern
among organelles. For example, PtdIns4P is predominantly found at
the Golgi complex, while PtdIns(3,4)P2, PtdIns(4,5)P2, and PtdIns(3,4,5)P3, which play important roles
in signal transduction, are concentrated at the plasma membrane. PtdIns3P
and PtdIns(3,5)P2, which regulate endosome fission and
fusion, are concentrated in early endosomes and late endosomes, respectively.[5]Consistent with the central roles of these
lipids, mutations in
the network of enzymes responsible for their synthesis and degradation
have been linked to a variety of diseases.[6] Phosphoinositide 3-kinase inhibitors have been proposed as novel
antiplatelet agents, to prevent thrombotic events in stroke and cardiovascular
diseases.[7] Defects in synaptojanin-1, a
PtdIns(4,5)P2 phosphatase that is widely expressed in neurons,
have been linked to Alzheimer’s disease and Down’s syndrome,[8,9] while mutations in SHIP2, a PtdIns(3,4,5)P3 phosphatase,
have been associated with type 2 diabetes.[10]This has spurred the development of methods capable of measuring
changes in these lipids. Nevertheless, despite the importance of phosphoinositides,
their identification and quantification remain a major challenge,
largely due to their low abundance and high polarity.[2] In the 1990s, their qualitative and quantitative analyses
were conducted through phosphoinositide deacylation combined with
the use of thin-layer chromatography for enrichment, anion-exchange
chromatography for separation, and 32P radioactive labeling
for detection.[11−13] The method has several limitations such as use of
radioactive materials, the challenge in labeling primary cells and
tissues, and the number of steps involved.Nonradioactive methods
using tandem mass spectrometry (MS/MS) have
been then developed to detect and quantify phosphoinositides. In 2002,
Wenk et al. introduced the use of MS/MS for phosphoinositides analysis.[14] The phosphoinositides were extracted by acidified
chloroform/methanol, and piperidine was applied as an ion-pairing
agent. Direct infusion and the precursor-ion scan mode targeting the
inositol phosphate fragment ions were utilized for phosphoinositides
analysis. The method could not however differentiate the phosphoinositides
positional isomers, was unable to identify PtdInsP3, and had relatively
low sensitivity for PtdInsP and PtdInsP2, at approximately 50 and
150 pmol, respectively.Nowadays, phosphoinositides are most
often measured by reversed-phase
liquid chromatography coupled to tandem mass spectrometry (RPLC-MS/MS).
In brief, phosphoinositides are extracted by acidified chloroform/methanol[15−19] or acidic n-butanol/chloroform extraction.[20] The extracted phosphoinositides are then derivatized
with TMS-diazomethane to methylate the phosphate groups,[16,19,20] deacylated with methylamine to
remove the acyl chains and produce glycerophosphoinositol phosphates
(GroPInsP),[18] or just directly analyzed
without any derivatization.[15,17] In the case of deacylated
or underivatized phosphoinositides, RPLC-electrospray ionization (RPLC-ESI)
is the method of choice and has the advantage of separating phosphoinositides
positional isomers.[15,18] The addition of an ion-pairing
reagent is also needed to shield the highly polar phosphate group
and facilitate isomers separation using reversed-phase chromatography,
which may contaminate the MS, cause ion suppression, and affect the
ionization pattern of ions when it is used for other purposes.[21,22] RPLC-ESI separation of methylated phosphoinositides is robust and
sensitive, but it is unable to differentiate the phosphoinositides
positional isomers.[16,20] Differentiating the positional
isomers is possible for methylated phosphoinositides if direct infusion
is used, but at the cost of adding high concentrations of lithium
ions, as well as the need of sophisticated analysis to determine the
positional isomers ratios based on the ratio of lithiated ions.[19]Recent developments in ion chromatography
(IC) allow conductivity
suppression by continuous online removal of high salt concentrations
leaving the analytes in pure water, which permits online coupling
of IC with MS. So far, IC was utilized with tandem mass spectrometry
(IC-MS/MS) for untargeted metabolic profiling and targeted screening
and quantification of metabolites such as carbohydrates, organic acids,
sugar phosphates, and nucleotides in different biological matrices.[23−25] However, its application to phosphoinositides analysis has not yet
been fully explored.In this study, we report the use of IC-MS/MS
to resolve the deacylated
phosphoinositides positional isomers for absolute quantification of
these isomers with high sensitivity in tissues and cells. We believe
that the developed method will greatly facilitate the analysis of
phosphoinositides and bring us an important step closer to the global
understanding of phosphoinositides signaling.
Experimental Section
Materials
Chemicals and reagents were obtained from
the following sources: MS-grade methanol (MeOH) from Biosolve (Valkenswaard,
The Netherlands); formic acid, 37% hydrochloric acid (HCl), chloroform
(CHCl3), and methylamine in MeOH from Sigma-Aldrich (Steinheim,
Germany); sodium chloride (NaCl), 1-butanol, and isopropanol (IPA)
from Merck (Darmstadt, Germany); Tris(hydroxymethyl)-aminomethane
(Tris) from Applichem (Darmstadt, Germany); sodium dodecyl sulfate
(SDS) from Roth (Karlsruhe, Germany); 16:0/16:0 PtdIns4P and 16:0/16:0
PtdIns(4,5)P2 α-fluorovinylphosphonate (PtdIns(4,5)P2-FP) from Echelon Biosciences (Salt Lake City, UT); and 17:0/20:4
PtdIns3P, 18:1/18:1 PtdIns(3,4)P2, 18:1/18:1 PtdIns(4,5)P2, 18:1/18:1 PtdIns(3,5)P2, and 17:0/20:4 PtdIns(3,4,5)P3 from Avanti Polar Lipids (Alabaster, AL). Ultrapure water
(18 MΩ cm at 25 °C) was obtained from an Elga Labwater
system (Lane End, U.K.). Bicinchoninic acid (BCA) assay was purchased
from Thermo Scientific (Schwerte, Germany). Platelets were activated
using collagen-related peptide (CRP, Richard Farndale, University
of Cambridge, U.K.) or thrombin from human plasma (Roche, Germany).
Ethical Regulations for Animal Samples
Four-week-old
male C57BL/6J mice (Charles River, Germany) were used. Male Wistar
rats were used at the age of 10 weeks in six independent preparations.
The animals were euthanized, and the hippocampi were dissected. All
animal experimentations were performed in accordance with the ARRIVE
guidelines for animal experimentation[26] and EU regulations, and approved by the local ethical committee.
Ethical Regulations for Human Samples
All volunteers
gave informed consent for blood samples. The platelet study was approved
by the institutional ethics committee (270/2011BO1) at the University
Hospital Tübingen (Germany) and complied with the Declaration
of Helsinki and good clinical practice guidelines.
Preparation
of Human Platelets
Blood from four individual
healthy volunteers was collected to obtain four individual samples
in ACD buffer (70 mM citric acid, 116 mM sodium citrate, 111 mM glucose,
pH 4.6) and centrifuged at 200g for 20 min. The obtained
platelet-rich plasma was added to modified Tyrode-HEPES (N-2-hydroxyethyl-piperazone-N′2-ethanesulfonic
acid) buffer (137 mM NaCl, 2 mM KCl, 12 mM NaHCO3, 5 mM
glucose, 0.3 mM Na2HPO4, 10 mM HEPES, pH 6.5).
After centrifugation at 900g for 10 min and removal
of the supernatant, the resulting platelet pellet was resuspended
in Tyrode-HEPES buffer (pH 7.4, supplemented with 1 mM CaCl2).
Platelet Stimulation Experiment
Freshly isolated and
resuspended human platelets in 100 μL at a concentration of
1 × 106 platelets/μL were stimulated with either
0.01 U/mL thrombin or 1 μg/mL CRP for 5 min. After centrifugation
for 5 min at 640g at 25 °C, the pellets were
shock-frozen in liquid nitrogen and stored at −80 °C.
Cell Culture
Mesenchymal stem cells (OP9) were grown
following a previously published protocol.[27] Briefly, the cells were grown in MEM with l-glutamine,
20% FBS, and 100 U/mL penicillin/streptomycin. Cultures were maintained
at 37 °C in humidified atmosphere with 5% CO2, and
the medium was renewed every 4 days. After reaching 80% confluence,
the cells were trypsinized, washed with PBS, and collected from culture
dish. The cells were aliquoted to 1 × 107 cells per
sample, centrifuged at 400g for 5 min, the supernatant
was removed, and the cell pellet were snap-frozen in liquid nitrogen.
Membrane Preparation from Rat Hippocampal Brain Tissue
Subcellular
fractionation of rat hippocampus was performed as described
earlier.[28] Rat hippocampal tissue (3.5
g) was homogenized in 10 mL/g buffer A (0.32 M sucrose, 5 mM HEPES,
pH 7.4) including protease inhibitor cocktail (PI) and phosphatase
inhibitor (PhosSTOP) and centrifuged at 1000g for
10 min. The pellet was rehomogenized and centrifuged in buffer A.
The resulting pellet 1 containing nuclei and cell debris was discarded,
and the supernatants were combined. The combined supernatants were
centrifuged at 12 000g for 20 min (Sorvall
RC6, F13-14 x 50cy rotor). The pellet P2 was rehomogenized in buffer
A and centrifuged as previously at 12 000g for 20 min. The resulting pellet was collected as the hippocampus
heavy membrane fraction.
Lipid Extraction
Acidified chloroform/methanol
(CHCl3/MeOH) extraction was carried out following the protocol
of
Clark et al.[16] For platelet samples, after
the addition of 242 μL of CHCl3, 484 μL of
MeOH, 23.6 μL of 1 M HCl, 170 μL water, and internal standard
(100 pmol of PtdIns(4,5)P2-FP) to the cell pellets containing
1 × 108 platelets, the mixture was allowed to stand
at room temperature for 5 min with occasional vortexing. Next, 725
μL of CHCl3 and 170 μL of 2 M HCl were added
to induce phase separation and the samples were centrifuged at 1500g for 5 min at room temperature (Eppendorf, Hamburg, Germany).
This created a two-phase system with an upper aqueous layer and a
protein interface. Then, the lower organic layer was transferred to
another tube and dried under a continuous stream of nitrogen (1 L/min
N2 at 25 °C).For pre-adipocytes and rat hippocampal
heavy membrane fraction, after the addition of 242 μL of CHCl3, 484 μL of MeOH, 25 μL of 50 mM NaOH, 170 μL
of water, and the internal standard (2 nmol of PI(4,5)P2-FP) to the cell pellets, the mixture was vortexed and sonicated
until homogenization. Afterward, 725 μL of CHCl3 was
added and the samples were centrifuged at 1500g for
5 min at room temperature. The resulting lower phase containing neutral
lipids was removed without disturbing the upper aqueous phase and
protein interphase. Next, 170 μL of 2 M HCl, 333 μL of
MeOH, and 667 μL of CHCl3 were added to the remaining
phase and the mixture was allowed to stand at room temperature for
5 min with occasional vortexing. The samples were then centrifuged
at 1500g for 5 min at room temperature. Next, the
lower organic layer was transferred to another tube and dried under
a continuous stream of nitrogen (1 L/min N2 at 25 °C).The lipid extracts were then deacylated following the protocol
of Jeschke et al.[18] The dried lipid extracts
were resuspended in 50 μL of methylamine in methanol/water/1-butanol
(46:43:11) and incubated at 53 °C for 50 min in a thermomixer
at 1000 rpm (Thermomixer Comfort; Eppendorf, Hamburg, Germany). Then,
25 μL of cold IPA was added to the mixture and the mixture was
dried under a continuous stream of nitrogen to obtain dried lipid
extracts (1 L/min N2 at 25 °C). The dried and deacylated
lipid extract was resuspended in 50 μL of water and stored at
−80 °C prior to further analysis.
Protein Concentration Determination
Methanol (1200
μL) was added to the remaining protein interphase and aqueous
upper phase, and the mixture was incubated at −80 °C for
3 h. Then, the mixture was centrifuged at 19 000g for 30 min at 4 °C, the supernatant was removed, and the remaining
protein pellet was dried under the fume hood. The resulting protein
pellet was then resuspended in 1% SDS, 150 mM NaCl, 50 mM Tris (pH
7.8), and the protein concentration was determined using the BCA assay.
IC-MS/MS
IC-MS/MS was conducted using a Dionex ICS-5000
instrument (Thermo Fischer Scientific, Darmstadt, Germany) connected
to a QTRAP 6500 instrument (AB Sciex, Darmstadt, Germany) that was
equipped with an electrospray ion source (Turbo V ion source). Chromatographic
separation was accomplished with a Dionex IonPac AS11-HC column (250
mm × 2 mm, 4 μm; Thermo Fischer Scientific) fitted with
a guard column (50 mm × 2 mm, 4 μm; Thermo Fisher Scientific).
A segmented linear gradient was used for separation of GroPInsP: Initial
15 mM potassium hydroxide (KOH), held at 15 mM KOH from 0.0 to 5.0
min, 15–25 mM KOH from 5.0 to 15.0 min, 50–65 mM KOH
from 15.0 to 30.0 min, 100 mM KOH from 30.0 to 34.0 min, 10 mM KOH
from 34.0 to 38.0 min, 100 mM KOH from 38.0 to 42.0 min, and 15 mM
KOH from 42.0 to 45.0 min. The IC flow rate was 0.38 mL/min, supplemented
post-column with 0.15 mL/min makeup flow of 0.01% FA in MeOH. The
temperatures of the autosampler, column oven, and ion suppressor were
set at 10, 30, and 20 °C, respectively. The injector needle was
automatically washed with water, and 5 μL of each sample was
loaded onto the column.The following ESI source settings were
used: curtain gas, 20 arbitrary units; temperature, 400 °C; ion
source gas I, 60 arbitrary units; ion source gas II, 40 arbitrary
units; collision gas, medium; ion spray voltage, −4500 V; declustering
potential, −150 V; entrance potential, −10 V; and exit
potential, −10 V. For scheduled selected reaction monitoring
(SRM), Q1 and Q3 were set to unit resolution. The collision energy
was optimized for each GroPInsP by direct infusion of the corresponding
deacylated standard. The scheduled SRM detection window was set to
3 min, and the cycle time was set to 1.5 s. Data were acquired with
Analyst version 1.6.2 (AB Sciex). Skyline (64-bit, 3.5.0.9319) was
used to visualize results, integrate signals over time, and quantify
all lipids that were detected by MS.[29]
Results and Discussion
Establishing Profiling Strategies for Phosphoinositides
We present here an improved quantitative IC-MS/MS workflow for
phosphoinositides
analysis, which includes the addition of standards, a modified extraction
and deacylation procedure, and an optimized IC method, resulting in
a comprehensive quantitative workflow (Figure ).
Figure 1
Schematic diagram of targeted phosphoinositides
analysis workflow
using an ion chromatography-QTRAP system. Phosphoinositides in platelets,
OP9 cells, and rat hippocampal brain tissue were extracted by acidified
chloroform/methanol and then deacylated with methylamine. The phosphoinositides
were then separated on an anion-exchange column by a KOH gradient
and analyzed using the SRM approach. Data analysis was conducted using
Skyline, and the absolute quantities of each positional isomers were
determined.
Schematic diagram of targeted phosphoinositides
analysis workflow
using an ion chromatography-QTRAP system. Phosphoinositides in platelets,
OP9 cells, and rat hippocampal brain tissue were extracted by acidified
chloroform/methanol and then deacylated with methylamine. The phosphoinositides
were then separated on an anion-exchange column by a KOH gradient
and analyzed using the SRM approach. Data analysis was conducted using
Skyline, and the absolute quantities of each positional isomers were
determined.
Extraction Strategies for Phosphoinositides
We reviewed
and compared earlier extraction strategies of phosphoinositides. As
a base, we chose the acidified chloroform/methanol strategy described
in Clark et al.,[16] which protonates the
phosphate groups on phosphoinositides headgroups to increase their
solubility in the organic phase. We then deacylated the phosphoinositides
with methylamine to remove the fatty acid chain and produce GroPInsP,
dried the GroPInsP with nitrogen stream, and reconstituted the extract
in water prior to IC-MS/MS analysis, as modified from the protocol
detailed by Jeschke et al.[18]The
extraction efficiency of the strategy was then validated by spiking
synthetic internal standards PtdIns(4,5)P2-FP into unstimulated
human platelets before or after extraction (Figure A). PtdIns(4,5)P2-FP is a metabolically
stabilized analogue of PtdIns(4,5)P2, which contains a
fluorovinylphosphonate group instead of a phosphodiester bond (Figure S4). The recoveries for PtdIns4P, PtdIns(4,5)P2, PtdIns(3,4,5)P3, and synthetic standard PtdIns(4,5)P2-FP were determined to be 103 ± 12, 109 ± 11, 134
± 13, and 54.5 ± 20%, respectively, suggesting that the
phosphoinositides were analyzed with good recoveries.
Figure 2
Extraction efficiency,
elution profile, and MS/MS spectra of phosphoinositide/GroPInsP
species. (A) Bar chart showing the peak area of the phosphoinositides
with endogenous and synthetic standards spiked into unstimulated human
platelets before (black) or after (white) extraction in triplicate.
The recoveries for PtdIns4P, PtdIns(4,5)P2, PtdIns(3,4,5)P3, and synthetic standard PtdIns(4,5)P2-FP were
103 ± 12, 109 ± 11, 134 ± 13, and 54.5 ± 20%,
respectively (n = 3 technical replicates). (B–D)
Fragment-ion spectra of (B) GroPInsP, (C) GroPInsP2, and
(D) GroPInsP3 obtained on QTRAP. Collision-induced dissociation
of these headgroups led to the formation of fragments that lost −C3H7O5P, −H2O, or −O3P molecules. (E) SRM extracted-ion chromatogram (XIC) of deacylated
phosphoinositide standard mixture. The three GroPInsP2 positional
isomers were separated using the optimized gradient. GroPIns3P and
GroPIns5P could not be resolved, but GroPIns4P could be separated.
The structure of each GroPInsP is also shown.
Extraction efficiency,
elution profile, and MS/MS spectra of phosphoinositide/GroPInsP
species. (A) Bar chart showing the peak area of the phosphoinositides
with endogenous and synthetic standards spiked into unstimulated human
platelets before (black) or after (white) extraction in triplicate.
The recoveries for PtdIns4P, PtdIns(4,5)P2, PtdIns(3,4,5)P3, and synthetic standard PtdIns(4,5)P2-FP were
103 ± 12, 109 ± 11, 134 ± 13, and 54.5 ± 20%,
respectively (n = 3 technical replicates). (B–D)
Fragment-ion spectra of (B) GroPInsP, (C) GroPInsP2, and
(D) GroPInsP3 obtained on QTRAP. Collision-induced dissociation
of these headgroups led to the formation of fragments that lost −C3H7O5P, −H2O, or −O3P molecules. (E) SRM extracted-ion chromatogram (XIC) of deacylated
phosphoinositide standard mixture. The three GroPInsP2 positional
isomers were separated using the optimized gradient. GroPIns3P and
GroPIns5P could not be resolved, but GroPIns4P could be separated.
The structure of each GroPInsP is also shown.
Optimization of IC Method for Phosphoinositides Analysis
The extracted and deacylated phosphoinositides headgroups were separated
by IC, which was equipped with an anion-exchange column, and eluted
with a KOH gradient according to the negative charges on the analyte
molecules. After the removal of highly concentrated hydroxide ions
by the ion suppressor, the output flow was mixed with a makeup flow
of 0.01% formic acid in MeOH and analyzed in an enhanced product-ion
scan experiment monitoring the fragment-ion spectra of the selected
precursor ions, as shown in Figure B−D. The use of IC instead of RPLC eliminated
the need of adding ion-pairing reagents, which could contaminate the
MS Instruments, while providing good separation to the GroPInsP isomers
(Figure E).We optimized the IC gradient for phosphoinositide separation to achieve
a comprehensive analysis of individual GroPInsP isomers. Based on
the results from previous studies, we evaluated different ion chromatography
separation gradients that are currently used in the field for metabolomics
analysis, and the results from two of these are reported (Figure ).[23,25] Gradients B [resolution (R), 100%] and C (R, 100%) yielded separation
that was better than that of gradient A (R, 70.2%) for GroPIns4P and
GroPIns3P. For GroPIns(3,4)P2, GroPIns(4,5)P2, and GroPIns(4,5)P2, GroPIns(3,5)P2, Gradients
C (R, 100 and 100%) and A (R, 104 and 96%) yielded separation that
was better than that of gradient B (R, 75 and 70%). All tested gradients
were unable to resolve GroPIns3P from GroPIns5P, which is rooted in
their structural similarity. The results of our HPLC gradient evaluations
indicate that the use of the optimized segmented linear gradient C
is the best choice for the separation of both GroPInsP and GroPInsP2 classes.
Figure 3
Comparison of three LC gradients. (A) Total ion chromatogram
(TIC)
of the GroPInsP and the IC gradient of gradients A, B, and C. The
left axis shows the relative abundance of the ions in the TIC, and
the right axis shows the concentration of KOH used in each gradient.
(B) XIC of the GroPInsP. For GroPIns4P and GroPIns3P, gradients C
(resolution (R), 100%) and B (R, 100%) yielded separation that was
better than that of gradient A (R, 70.2%). All three gradients failed
to resolve GroPIns3P from GroPIns5P. (C) XIC of GroPInsP2. For GroPIns(3,4)P2, GroPIns(4,5)P2, GroPIns(4,5)P2, and GroPIns(3,5)P2, gradients C (R, 100 and 100%)
and A (R, 104 and 96%) yielded separation that were better than that
of gradient B (R, 75 and 70%). The IC gradients of gradients A, B,
and C are derived from refs (23) and (25) and this study, respectively.
Comparison of three LC gradients. (A) Total ion chromatogram
(TIC)
of the GroPInsP and the IC gradient of gradients A, B, and C. The
left axis shows the relative abundance of the ions in the TIC, and
the right axis shows the concentration of KOH used in each gradient.
(B) XIC of the GroPInsP. For GroPIns4P and GroPIns3P, gradients C
(resolution (R), 100%) and B (R, 100%) yielded separation that was
better than that of gradient A (R, 70.2%). All three gradients failed
to resolve GroPIns3P from GroPIns5P. (C) XIC of GroPInsP2. For GroPIns(3,4)P2, GroPIns(4,5)P2, GroPIns(4,5)P2, and GroPIns(3,5)P2, gradients C (R, 100 and 100%)
and A (R, 104 and 96%) yielded separation that were better than that
of gradient B (R, 75 and 70%). The IC gradients of gradients A, B,
and C are derived from refs (23) and (25) and this study, respectively.To prove the robustness of the developed method, the stability
of the IC gradient was validated across 120 injections of standards
and phosphoinositides containing samples derived from human platelets,
OP9 cells, and rat brain fractions (Figure ). The retention times of GroPIns4P, GroPIns(4,5)P2, GroPIns(3,4,5)P3, and GroPIns(4,5)P2-FP averaged at 13.18 ± 0.11, 22.13 ± 0.08, 28.87 ±
0.24, and 22.03 ± 0.09 min, respectively, suggesting that the
IC method for GroPInsP separation is highly reproducible.
Figure 4
Elution time
reproducibility of the developed workflow. (A) Dot
plot and (B) violin plot showing the elution time of the GroPInsP
in a large number of injections of standards and phosphoinositide-containing
samples derived from human platelets, OP9 cells, and rat hippocampal
brain tissue (n = 43–141 LC-MS runs).
Elution time
reproducibility of the developed workflow. (A) Dot
plot and (B) violin plot showing the elution time of the GroPInsP
in a large number of injections of standards and phosphoinositide-containing
samples derived from human platelets, OP9 cells, and rat hippocampal
brain tissue (n = 43–141 LC-MS runs).
Quantification of Phosphoinositides Using
Targeted Mass Spectrometry
Targeted analysis of phosphoinositides
was performed using an SRM
approach. Molecular ions selected in the first quadrupole were fragmented
in the second quadrupole using collision parameters optimized to give
the highest fragment ions intensity. The collision energy was chosen
to be −32 eV for GroPIns(3,4,5)P3 and −27
eV for all other precursor molecules (Table S1). The deacylation of the phosphoinositides removed the fatty acyl
chain, making it more hydrophilic and thus facilitating its separation
through IC, simplifying the mass spectra and allowing the isomer analysis
at the class level. However, some of the phosphoinositides headgroups
have the same number of phosphate groups and similar MS2 fragmentation patterns that were indistinguishable (Figure S1). Therefore, an optimized LC gradient
was necessary to separate and differentiate the different GroPInsP
and GroPInsP2 isomers (Figure E, gradient C in Figure A–C).To quantify the phosphoinositides
in complex biological matrices, we used the internal calibration curve
approach to achieve maximum accuracy. We spiked known amounts of phosphoinositides
and 100 pmol of internal standard PtdIns(4,5)P2-FP into
1 × 108 unstimulated human platelets. The area ratio
was calculated by dividing the highest-intensity fragment at −27
eV for GroPInsP and GroPInsP2 and at −32 eV for
GroPInsP3 by that of the internal standard at −27
eV. The resulting calibration curves ranged from 312.5 fmol to 10
pmol with a high degree of linearity (R2 ≈ 0.99) (Figure ). These results indicate that the use of a synthetic internal
standard, PtdIns(4,5)P2-FP, to correct for recovery through
the extraction, deacylation, and the IC-SRM assay is a very sensitive
and robust method to absolutely quantify all phosphoinositides species
in cells.
Figure 5
Internal standard calibration curve for absolute quantification
of GroPInsP. A known amount of phosphoinositides and 100 pmol of internal
standard were spiked into unstimulated human platelets extracts, and
then the phosphoinositides were extracted and deacylated using the
workflow. The areas under the extracted-ion chromatogram peak of (A)
GroPIns3P, (B) GroPIns4P, (C) GroPIns(3,4,5)P3, (D) GroPIns(3,4)P2, (E) GroPIns(4,5)P2, and (F) GroPIns(3,5)P2 were divided by that of the internal standard, and the area
ratio was plotted against the amount of the species spiked. The resulting
calibration curve, data points, and R2 value are shown (n = 3 technical replicates).
Internal standard calibration curve for absolute quantification
of GroPInsP. A known amount of phosphoinositides and 100 pmol of internal
standard were spiked into unstimulated human platelets extracts, and
then the phosphoinositides were extracted and deacylated using the
workflow. The areas under the extracted-ion chromatogram peak of (A)
GroPIns3P, (B) GroPIns4P, (C) GroPIns(3,4,5)P3, (D) GroPIns(3,4)P2, (E) GroPIns(4,5)P2, and (F) GroPIns(3,5)P2 were divided by that of the internal standard, and the area
ratio was plotted against the amount of the species spiked. The resulting
calibration curve, data points, and R2 value are shown (n = 3 technical replicates).The method’s limit of detection (LOD) and
limit of quantification
(LOQ) were considered as the analyte concentration required to produce
a signal intensity that is 3 times or 10 times higher than the noise
signal. Using these criteria, GroPIns(3,4,5)P3 could be
detected in unstimulated extracts with as little as 312.5 fmol (S/N
> 3) and quantified at 625 fmol (S/N > 10) (Figure S2).Compared with the most sensitive method reported
so far, which
has a limit of detection of 250 pg (equivalent to 250 fmol) C18:0/C20:4-PtdIns(3,4,5)P3,[16] the current method provided
comparable sensitivity to positional isomers resolution.
Phosphoinositides
Profile in Complex Biological Samples
To illustrate the effectiveness
of our workflow, we applied it to
complex biological samples including cell culture (pre-adipocyte OP9
cells), rat brain tissue, and human platelets; successfully quantified
the phosphoinositides positional isomers (Figures and S3); and
quantified rapid phosphoinositides profile changes in platelets upon
ligand stimulation (Figure ).
Figure 6
Resting phosphoinositides amount in platelets, OP9 pre-adipocytes,
and rat hippocampus heavy membrane fraction. Bar chart showing phosphoinositides
profile in different biological samples, including human platelets,
OP9 pre-adipocytes cell culture, and rat hippocampus heavy membrane
fraction (n = 3 biological replicates).
Figure 7
Effect of CRP and thrombin on human platelets phosphoinositides
profile. Box plot showing changes in the phosphoinositides species,
including (A) PtdIns4P, (B) PtdIns(3,4)P2, (C) PtdIns(4,5)P2, and (D) PtdIns(3,4,5)P3 in human platelets after
thrombin and CRP stimulation, quantified by internal calibration curve,
with a half-violin plot showing the distribution of phosphoinositides
of each donor. Each color corresponds to four separate donors as biological
replicates, and each dot corresponds to one of the technical duplicates.
*P < 0.05, **P < 0.01, and
***P < 0.001 indicate statistically significant
differences. ns, not significant. N.D., not detectable (n = 4 biological replicates).
Resting phosphoinositides amount in platelets, OP9 pre-adipocytes,
and rat hippocampus heavy membrane fraction. Bar chart showing phosphoinositides
profile in different biological samples, including human platelets,
OP9 pre-adipocytes cell culture, and rat hippocampus heavy membrane
fraction (n = 3 biological replicates).Effect of CRP and thrombin on human platelets phosphoinositides
profile. Box plot showing changes in the phosphoinositides species,
including (A) PtdIns4P, (B) PtdIns(3,4)P2, (C) PtdIns(4,5)P2, and (D) PtdIns(3,4,5)P3 in human platelets after
thrombin and CRP stimulation, quantified by internal calibration curve,
with a half-violin plot showing the distribution of phosphoinositides
of each donor. Each color corresponds to four separate donors as biological
replicates, and each dot corresponds to one of the technical duplicates.
*P < 0.05, **P < 0.01, and
***P < 0.001 indicate statistically significant
differences. ns, not significant. N.D., not detectable (n = 4 biological replicates).
Phosphoinositides
Profile in Resting and Stimulated Human Platelets
In resting
platelets, three phosphoinositides species, PtdIns4P,
PtdIns(3,4)P2, and PtdIns(4,5)P2, were identified
and quantified, at 94.7 ± 11.1 pmol/1 × 108 platelets,
3.1 ± 0.2 pmol/1 × 108 platelets, and 59.2 ±
12.4 pmol/1 × 108 platelets, respectively (Figure S3A). Previous studies, which used a combination
of radioactive labeling, TLC, and HPLC to analyze phosphoinositides
in platelets, determined the level of PtdIns4P and PtdIns(4,5)P2 to be 150–245 pmol/1 × 108 platelets
and 55–139 pmol/1 × 108 platelets, respectively.
The phosphoinositides level determined in the present study showed
high consistency with these reports, thus further illustrating the
reliability of the introduced workflow (Figure S3).[30−32]To prove that the workflow can also catch the
transient changes in phosphoinositides signaling, we analyzed the
phosphoinositides profile in stimulated human platelets and assessed
the effect of different agonists such as collagen-related peptide
(CRP) and thrombin on phosphoinositides metabolism (Figure ). CRP and thrombin treatment
of platelets has been previously reported to activate platelets through
platelet receptor glycoprotein VI (GPVI) and protease-activated receptors
(PARs), respectively.[33,34] It has been reported that 10
min CRP treatment in human platelets increased the level of PtdIns4P
by 1.5-fold and PtdIns(4,5)P2 by 1.25-fold, as well as
increased the level of PtdIns(3,4,5)P3.[35] However, that study was unable to differentiate PtdIns(3,4)P2 from PtdIns(4,5)P2, resulting in loss of important
signaling information. Knowing and differentiating the levels of PtdIns(4,5)P2 and PtdIns(3,4)P2 would provide information about
the formation and flux change of PtdIns(3,4,5)P3 because
PtdIns(3,4)P2 is a product of SHIP1 and SHIP2, two PtdIns(3,4,5)P3 5-phosphatases that are known to regulate the level of PtdIns(3,4,5)P3 in platelets.[36]Here, we
were able to absolutely quantify each individual species
in unstimulated, CRP, and thrombin-stimulated platelets (Figure ). Similar to previous
studies, we found that the levels of PtdIns4P and PtdIns(4,5)P2 were increased by 2-fold, from 122.3 ± 27.8 to 243.7
± 46.1 pmol/mg protein and 1.5-fold, from 78.8 ± 13.7 to
118.1 ± 20.5 pmol/mg protein, respectively, after 5 min of CRP
treatment, which is due to the increased production via PtdIns4P toward
PtdIns(4,5)P2 by phosphoinositides kinase PIP4K and PIP5K
as previously reported.[30,37] The most prominent
change was observed for PtdIns(3,4)P2, which increased
4.5-fold, from 4.0 ± 0.8 to 17.1 ± 3.5 pmol/mg protein after
5 min of stimulation, resulting most probably from the dephosphorylation
of PtdIns(3,4,5)P3 by phosphoinositides phosphatase SHIP
or other poly-phosphatases present in platelets.[36,38] On the other hand, the use of 0.01 U/mL thrombin as stimulus was
unable to cause a significant change in PtdIns4P and PtdIns(4,5)P2 profiles, but it led to a 2-fold increase in PtdIns(3,4)P2, from 4.0 ± 0.8 to 8.2 ± 2.6 pmol/mg protein.
Phosphoinositides Profile in OP9 Pre-Adipocytes
OP9
cells are pre-adipocytes that can rapidly differentiate into different
types of adipocytes.[39] All phosphoinositides
species could be identified, including PtdIns4P and PtdIns(4,5)P2 (Figure ).
The amounts of PtdIns3P + PtdIns5P, PtdIns4P, PtdIns(3,4)P2, PtdIns(4,5)P2, and PtdIns(3,4,5)P3 are 11.1
± 4.6, 160 ± 4, 21.8 ± 8.0, 630 ± 53, and 18.0
± 5.4 pmol/mg protein, respectively. The higher variety and the
detection of PtdIns(3,4,5)P3 can be explained by the existence
of insulin-like growth factor 1 (IGF1) in FBS in culture media, which
stimulated the IGF1 receptor on pre-adipocyte surface and led to production
of PtdIns(3,4,5)P3 and derived species.[40,41] Previous studies have also reported the production of PtdIns(3,4,5)P3 in other pre-adipocyte cell lines such as 3T3-L1 upon IGF1
stimulation, which induced pre-adipocytes growth and survival.[42,43] PtdIns3P, PtdIns5P, and PtdIns(3,4)P2 were also detected
in this study, as the dephosphorylation product of PtdIns(3,4,5)P3.[36]
Phosphoinositides Profile
in Rat Hippocampus
In the
heavy membrane fraction enriched from rat hippocampus, we identified
and quantified three phosphoinositides species, PtdIns4P, PtdIns(4,5)P2, and PtdIns(3,4,5)P3, at 901 ± 116, 1560
± 540, and 6.8 ± 2.0 pmol/mg protein, respectively (Figure ). Compared to previous
studies that determined the levels of PtdIns4P and PtdIns(4,5)P2 to be 1400 and 3860 pmol/mg protein, respectively (assuming
the protein content in rat hippocampus to be 114 mg/g protein[44]), the phosphoinositides levels determined in
the present study showed high consistency with these reports, and
is further able to detect PtdIns(3,4,5)P3 (Figure S3), demonstrating the higher sensitivity
of the chosen approach.[45]
Conclusions
In this study, we developed an IC-SRM-based workflow that significantly
increases the isomer resolution in phosphoinositides analysis and
applied it to study the phosphoinositide composition in platelets,
pre-adipocytes, and rat hippocampus membrane fraction. Our workflow
was able to separate the biologically relevant GroPInsPs isomers except
GroPIns3P and GroPIns5P and achieved LOD and LOQ for phosphoinositides
at 312.5 and 625 fmol, respectively, thereby providing absolute amounts
of different isomers. The workflow improves sample preparation and
analysis and thus yields a higher level of confidence for phosphoinositide
separation and quantification. Application of the workflow for different
cell types and tissues demonstrates its versatility and potential
to unravel specific roles played by each of the phosphoinositides.
Authors: Karl Burgess; Darren Creek; Paul Dewsbury; Ken Cook; Michael P Barrett Journal: Rapid Commun Mass Spectrom Date: 2011-11-30 Impact factor: 2.419